Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Pliant Therapeutics, Inc.
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06097260CT.gov Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis | — | Terminated | — | — | — |
NCT05621252CT.gov Imaging Evaluation of PLN-74809 in Participants With IPF (PLN-74809) | — | Completed | — | — | — |
NCT04396756CT.gov Evaluation of Efficacy and Safety of PLN-74809 in Patients With Idiopathic Pulmonary Fibrosis | — | Completed | — | — | — |
NCT04072315CT.gov Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/ | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Idiopathic Pulmonary Fibrosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Bexotegrast (this asset) | Pliant Therapeutics, Inc. | P2 | B · 60 |
| Pirfenidone | Endeavor Biomedicines, Inc. | P4 | A |
| Acetylcysteine | Endeavor Biomedicines, Inc. | P4 | BBB |
| Nintedanib | Mannkind Corporation | P4 | BBB |
| hsk44459 | Haisco Pharmaceutical Group Co., Ltd. | P3 | BB |
| Prednisone | Fondation Hôpital Saint-Joseph | P3 | BB |
| Nerandomilast | Boehringer Ingelheim | P3 | BB |
| Sildenafil | Hoffmann-La Roche | P4 | BB |
| hec585 | Sunshine Lake Pharma Co., Ltd. | P3 | B |
+42 more in the Idiopathic Pulmonary Fibrosis cohort
Other indications for Bexotegrast
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Primary Sclerosing Cholangitis | — | P2 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Bexotegrast in Idiopathic Pulmonary Fibrosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/bexotegrast-idiopathic-pulmonary-fibrosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →